reindeer830, press release today on IPIX's flagshi
Post# of 714
(Total Views: 188)
Posted On: 04/27/2020 1:39:45 PM
Re: reindeer830 #170
reindeer830, press release today on IPIX's flagship drug Brilacidin, which has completed Phase 2 clinical trials for OTHER applications, but which surprised shareholders by turning out to have antiviral activity in addition to anti-inflammatory and antibiotic activity. Since COVID is a virus that can cause severe inflammation (cytokine storm) and secondary bacterial infections, it is possible that this drug may be deemed useful for COVID treatment. It's one of about 10 drugs that have been shown to have anti-viral activity in animal-cell studies, and is far enough advanced in human clinical trials that a Phase 3 trial could be started on COVID patients. Please check the ipharminc.com website and the IPIX board here for more information.
Here's a link to today's press release, as posted on the IPIX board:
https://investorshangout.com/post/view?id=5748466
I think all of the moderators here have been a little squeamish about posting about IPIX on this board, because we are trying to make this a general COVID board, not IPIX-2.0
Here's a link to today's press release, as posted on the IPIX board:
https://investorshangout.com/post/view?id=5748466
I think all of the moderators here have been a little squeamish about posting about IPIX on this board, because we are trying to make this a general COVID board, not IPIX-2.0
(0)
(0)Scroll down for more posts ▼